Benjamin Stolte
Impact in
Papers in
- Genetics 25
- Neurogenetic and Muscular Disorders Research 25
-
- Myasthenia Gravis and Thymoma 3
- Amyotrophic Lateral Sclerosis Research 2
- Co-authors
- Tim Hagenacker (24 shared papers)Christoph Kleinschnitz (22 shared papers)Kathrin Kizina (12 shared papers)Andreas Totzeck (13 shared papers)Andreas Thimm (10 shared papers)Mark Obermann (1 shared paper)Dagny Holle (1 shared paper)Hans‐Christoph Diener (1 shared paper)
In The Last Decade
Benjamin Stolte
44 papers receiving 1.4k citations
Benjamin Stolte's Hit Papers
Peers
Comparison fields: 5 of 69
- Genetics 764
- Neurology 366
- Pharmacy 33
- Speech and Hearing 23
- Neurology 37
Countries citing papers authored by Benjamin Stolte
This map shows the geographic impact of Benjamin Stolte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Stolte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Stolte more than expected).
Fields of papers citing papers by Benjamin Stolte
This network shows the impact of papers produced by Benjamin Stolte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Stolte. The network helps show where Benjamin Stolte may publish in the future.
Co-authors
The 25 scholars most cited alongside Benjamin Stolte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study Hit paper breakdown → | 2020 | 255 |
| 2 | Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study Hit paper breakdown → | 2023 | 188 |
| 3 | Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2023 | 178 |
| 4 | 2014 | 74 | |
| 5 | 2018 | 63 | |
| 6 | 2022 | 62 | |
| 7 | 2021 | 50 | |
| 8 | 2021 | 48 | |
| 9 | 2019 | 46 | |
| 10 | 2024 | 41 | |
| 11 | 2020 | 38 | |
| 12 | 2022 | 32 | |
| 13 | 2020 | 30 | |
| 14 | 2021 | 30 | |
| 15 | 2021 | 27 | |
| 16 | 2021 | 25 | |
| 17 | 2019 | 24 | |
| 18 | 2019 | 24 | |
| 19 | 2021 | 22 | |
| 20 | 2011 | 21 |
About Benjamin Stolte
Benjamin Stolte is a scholar working on Genetics, Neurology, Speech and Hearing, Pharmacy and Radiology, Nuclear Medicine and Imaging, having authored 46 papers that have together received 1.5k indexed citations. Recurring topics across this work include Neurogenetic and Muscular Disorders Research (25 papers), Myasthenia Gravis and Thymoma (3 papers), Acute Ischemic Stroke Management (2 papers), Amyotrophic Lateral Sclerosis Research (2 papers), Radiation Dose and Imaging (2 papers), Adolescent and Pediatric Healthcare (2 papers), Nursing care and research (1 paper) and Polyomavirus and related diseases (1 paper). The work is most often cited by research in Genetics (764 citations), Neurology (366 citations), Pharmacy (33 citations), Speech and Hearing (23 citations) and Neurology (37 citations). Benjamin Stolte has collaborated with scholars based in Germany, France and Austria. Frequent co-authors include Tim Hagenacker, Christoph Kleinschnitz, Kathrin Kizina, Andreas Totzeck, Andreas Thimm, Mark Obermann, Dagny Holle, Hans‐Christoph Diener, Steffen Naegel and Michael Forsting. Their work appears in journals such as Therapeutic Advances in Neurological Disorders, European Journal of Neurology, Journal of Neurology, The Lancet Neurology and Frontiers in Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.